**EPP Light Dosimeter Impact Statement**

For patients with erythropoietic protoporphyria (EPP) who live with severe, painful photosensitivity, our team will develop novel digital biomarkers to support disease monitoring and to serve as clinical trials endpoints. Using a wearable light dosimeter, we will quantitatively measure light exposure. Simultaneously, using the hand-held device that measures fluorescence, we will quantify the cutaneous accumulation of EPP’s light-reactive chemical called protoporphyrin. Developing and testing these digital biomarkers will empower patients to take control of their own disease and will bring new therapies to patients.